ORIC-533
ORIC-533-01
Phase 1 small_molecule completed
Quick answer
ORIC-533 for Relapsed or Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at Oric Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Oric Pharmaceuticals
- Indication
- Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed